Humanized anti-CCR2 Antibody for the Therapy of MS and RA
Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.
Further information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Thermodynamics-Inspired Laser Beam Shaping Sparks a Ray of Hope
Inspired by ideas from thermodynamics, researchers at the University of Rostock and the University of Southern California have developed a new method to efficiently shape and combine high-energy laser beams….
A Breath of Fresh Air: Advanced Quantum Calculations Enable COF-999 CO₂ Adsorption
Quantum chemical calculations at HU enable the development of new porous materials that are characterized by a high absorption capacity for CO2 Climate experts agree: To overcome the climate crisis,…
Why Global Droughts Tied to Climate Change Have Left Us Feeling Under the Weather
A study led by the Swiss Federal Institute for Forest, Snow and Landscape Research WSL shows that there has been a worrying increase in the number of long droughts over…